CTLA4 and non-small cell lung carcinoma: Some examples include anti-PD-1/PD-L1 and anti-CTLA4 inhibitors, which have been shown to be effective for treating melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), breast carcinoma (BC) as well as other cancers (5, 6).